Tag: Lecanemab

In clinical trials for the Alzheimer's medication LEQEMBI (lecanemab), up to 12.6% of patients experienced brain swelling (ARIA-E) and 17.3% experienced brain bleeding (ARIA-H), which was higher than in the placebo group. While often asymptomatic, these side effects can, in rare cases, manifest with serious, stroke-like symptoms or lead to fatal brain hemorrhages, raising concerns about if **LEQEMBI can cause a stroke**. The U.S. Food and Drug Administration (FDA) has issued a black box warning to highlight this significant safety risk.

In the pivotal Clarity AD clinical trial, 12.6% of participants treated with Leqembi developed brain swelling (ARIA-E), a condition where confusion can be a key symptom [1.4.6]. The question of 'Can Leqembi cause confusion?' is directly linked to this and other potential side effects.

As of 2025, the U.S. Food and Drug Administration (FDA) has granted full approval to two amyloid antibodies for treating early-stage Alzheimer's disease: lecanemab (Leqembi) and donanemab (Kisunla) [1.2.1, 1.2.3, 1.2.4]. This article answers: **what amyloid antibodies are FDA approved** and details their use.

In clinical trials, common Leqembi side effects, such as infusion reactions and headaches, typically lasted for a few days to several weeks before resolving. However, the duration of side effects can vary significantly depending on the type and severity, with some serious adverse events like ARIA taking months to fully resolve.

According to the Alzheimer's Association, medications cannot cure Alzheimer's disease but can temporarily improve symptoms. The question of 'what is the best drug to improve memory?' is complex and highly dependent on the underlying cause of a person's cognitive difficulties. For most people, a combination of lifestyle changes and targeted medical intervention is the most effective approach to supporting brain health.